Molzym - Reveal DNA
Molzym was founded as a privately owned enterprise in Bremen, North-West Germany, in 2003. Ever since, Molzym has been committed to the development of innovative solutions to serve biological research and diagnosis of infectious diseases. Our developmental efforts are particularly focused on new processes enabling and facilitating the molecular diagnosis of infectious diseases caused by bacteria and fungi. Meanwhile, more than 50 high quality products are available for molecular microbial analysis by PCR- and NGS-based methods in 30 countries worldwide.
Molzym manufactures ultra-clean and highly active amplification reagents and kits for microbial nucleic acid extraction from a variety of specimens. In particular, reagents and consumables are supplied free of contaminating microbial NA – guaranteed lot by lot. Our customers appreciate the ability of increasing the number of amplification cycles and thus lowering the limit of detection dramatically without false positive results arising from contaminating microbial DNA. Another core expertise is Molzym’s unique technology of the depletion of human DNA, a well-known factor negatively influencing sensitive PCR and microbiome analysis at low microbial loads.
Quality Standard & Quality Assurance
Molzym is certified according to EN ISO 13485:2016.
As manufacturer and supplier of medical devices, the Molzym team is constantly working to ensure the consistently excellent quality of our products. In accordance with the requirements of the underlying legal standards, we have successfully implemented a documented quality management system.
A copy of the certificate can be downloaded here.
Products & Automation
MolYsis™ is Molzym’s proprietary technology of human DNA depletion allowing targeted isolation of microbial DNA from a variety of clinical samples, including whole blood, CSF, BAL, joint aspirates, tissue biopsies, abscesses and other material. Ultra-pure, DNA-free PCR reagents and master mixes allow for the precise detection and monitoring of aetiologies of infectious diseases in humans and animal models. Complete assays for the broad-range amplification of selected regions of the 16S and 18S rRNA genes of bacteria and fungi are available for PCR analysis at 40 cycles. Basic and dye master mixes can be used with custom primers for PCR and Real-Time PCR analysis.
The latest development is a walk-away robotic system, SelectNA™plus, for the fully automated human DNA depletion and extraction of microbial DNA from clinical and other material. SelectNA™plus conveys utmost technical advances to the demands for contamination-free and low-hands-on processing of samples for highest detection sensitivity of pathogens.
With SepsiTest™-UMD and Micro-Dx™, Molzym offers two CE-marked in-vitro diagnostic solutions for the culture-independent detection of pathogens causing various diseases. Both kits include reagents for the depletion of human DNA and the targeted isolation of microbial DNA from a variety of clinical samples, e.g. whole blood, CSF, BAL, joint aspirates, tissue biopsies, abscesses and other materials. Manual DNA isolation can be accomplished with SepsiTest™-UMD and with Micro-Dx™ the process is fully automated on the SelectNA™plus robot. Precise detection is performed with broad-range 16S/18S PCR and sequencing analysis to identify the pathogens down to the species level. Both assays are especially applicable for samples which were negative after culturing, e.g. due to prior antibiotic treatment or fastidious growth requirements.
Molzym offers a service for the decontamination of customized master mixes from microbial DNA for improved assay performance at increased amplification cycles. Molzym offers opportunities for collaborations that are directed to the development and manufacturing of individualized, pre-analytic and analytic adaptations, including automated DNA isolation. Molzym has developed a broad portfolio of patented technologies and reagents for pathogen-DNA enrichment, isolation and detection, including PCR and NGS applications.